| Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 20225909 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: High-altitude pulmonary hypertension (HAPH) is a public health problem in mountainous areas of the world. Treatment options for this condition are unsatisfactory. Recent interest in use of selective phosphodiesterase type 5 (PDE5) inhibitors for pulmonary hypertension has suggested a possible role for these agents in the treatment of HAPH. Preliminary data from several small studies have shown beneficial haemodynamic effects of empirical PDE5 treatment of HAPH but the results of these studies have been challenged. OBJECTIVE: We performed a meta-analysis to explore the potential therapeutic effects of PDE5 inhibitors for HAPH. METHODS: Randomized controlled trials were identified to test the effects of PDE5 inhibitors in HAPH by searching PubMed (inception to June 2009). A standardized protocol with predefined criteria was used to extract details on study design, Jadad score, demographic data, interventions and outcomes. The main outcomes assessed were cardiopulmonary parameters. Treatment effects for continuous variables were presented as weighted mean differences with 95% confidence intervals. RESULTS: Ten clinical trials were identified and included for the meta-analysis. The weighted mean difference in systolic pulmonary artery pressure post-treatment at rest in PDE5 inhibitor-treated subjects was -7.51 mmHg (95% CI -10.87, -4.16; p < 0.0001) compared with controls, whereas the analysis of systolic blood pressure and heart rate demonstrated that no significant effects were observed in the active treatment group at rest and during exercise. CONCLUSIONS: The available evidence suggests PDE5 inhibitors can attenuate altitude-induced pulmonary hypertension without significantly affecting systemic blood pressure or heart rate. |
| | |
Authors:
|
Bo Jin; Xin-Ping Luo; Huan-Chun Ni; Hai-Ming Shi |
Related Documents
:
|
9605369 - The effects of nitric oxide inhalation on respiratory mechanics and gas exchange during... 16797089 - Improved right ventricular-vascular coupling during active pulmonary hypertension. 14605079 - Clinical and exercise test determinants of survival after cardiac transplantation. 8997619 - Nitric oxide regulation of tp receptor-mediated pulmonary vasoconstriction in the anest... 1689429 - Acute hemodynamic effects of nilvadipine, a new calcium channel blocker, in patients wi... 3170419 - Effects of increased pulmonary vascular tone on gas exchange in canine oleic acid pulmo... 6427499 - Open-loop analysis of paco2 oscillation in the dog. 3607329 - Comparison of mouth and oesophageal pressure fluctuations during panting against an occ... 20097689 - Kidney flow and function in hypertension: protective effects of pycnogenol in hypertens... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical drug investigation Volume: 30 ISSN: 1173-2563 ISO Abbreviation: Clin Drug Investig Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-03-15 Completed Date: 2010-05-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9504817 Medline TA: Clin Drug Investig Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 259-65 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Altitude Sickness
/
drug therapy Blood Pressure / drug effects Cyclic Nucleotide Phosphodiesterases, Type 5 / antagonists & inhibitors* Exercise Heart Rate / drug effects Humans Hypertension, Pulmonary / drug therapy* Phosphodiesterase Inhibitors / adverse effects, therapeutic use* Pulmonary Artery / physiopathology Randomized Controlled Trials as Topic Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dose-Finding Studies of Ketoprofen in the Management of Fever in Children: Report on Two Randomized,...
Next Document: Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by t2* MRI.